Intensifying Insulin Therapy: What Options Are Available to Patients with Type 2 Diabetes?
-
Published:2013-09
Issue:9
Volume:126
Page:S28-S37
-
ISSN:0002-9343
-
Container-title:The American Journal of Medicine
-
language:en
-
Short-container-title:The American Journal of Medicine
Author:
Meneghini Luigi F.
Reference44 articles.
1. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study);Garber;Diabetes Obes Metab,2006
2. Pramlintide, the synthetic analog of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk;Hoogwerf;Vasc Health Risk Manag,2008
3. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6);Buse;Lancet,2009
4. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial;Buse;Ann Intern Med,2011
5. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets;DeVries;Diabetes Care,2012
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献